8-K: Telesis Bio Reports First Quarter 2024 Results: Revenue Declines, Operating Expenses Reduced

Telesis Bio's first quarter 2024 results show a decrease in revenue compared to the same period last year, but also a significant reduction in operating expenses.

Summary

• Telesis Bio announced its financial results for the first quarter of 2024, reporting a revenue of $3.4 million, down from $6.3 million in the same quarter of 2023.
• The revenue decrease was primarily due to a $1.7 million drop in product revenue, a $1.0 million decrease in collaboration revenue, and a $0.4 million decrease in service revenue, partially offset by a $0.2 million increase in royalty and other revenue.
• Product revenue from BioXp capital equipment instruments decreased by $1.6 million, and revenue from BioXp kits decreased by $0.1 million.
• Service revenue declines were largely due to commercial team turnover at the Eton subsidiary.
• Collaboration revenue decreased due to the completion of deferred revenue amortization from the Pfizer contract in the fourth quarter of 2023.
• Gross margin percentage was 42% in Q1 2024, compared to 56% in Q1 2023, primarily due to lower revenue from higher margin collaboration research programs and fewer sales of higher margin BioXp 9600 systems.
• Operating expenses were reduced by 31% year-over-year, from $14.5 million in Q1 2023 to $10.0 million in Q1 2024, largely due to a restructuring program in the fourth quarter of 2023.
• Net loss for the quarter was $8.6 million, an improvement from the $11.1 million loss in the same period last year.
• Net loss per share was $5.52, compared to $6.75 in the prior year, both adjusted for a 1-for-18 reverse stock split.
• Cash, cash equivalents, restricted cash, and investments totaled $15.7 million as of March 31, 2024, down from $19.3 million at the end of 2023.
• Long-term notes payable were $5.2 million as of March 31, 2024.

Sentiment

Score: 5

Explanation: The document presents mixed results with a significant revenue decline offset by cost reductions and strategic focus. The lack of forward guidance adds uncertainty.

Positives

• Operating expenses decreased by 31% year-over-year, indicating improved cost management.
• Net loss improved from $11.1 million to $8.6 million year-over-year.
• The company is seeing increased adoption of its BioXp mRNA solutions, with 40% of new customers indicating mRNA as their primary workflow.
• The strategic collaboration with Pfizer is progressing well.
• The company is focusing on the commercialization of its Gibson SOLA platform.

Negatives

• Total revenue decreased significantly from $6.3 million to $3.4 million year-over-year.
• Product revenue decreased by $1.7 million, with BioXp capital equipment sales down by $1.6 million.
• Collaboration revenue decreased by $1.0 million due to the completion of deferred revenue amortization from the Pfizer contract.
• Gross margin percentage decreased from 56% to 42% year-over-year.
• Cash reserves decreased from $19.3 million to $15.7 million during the quarter.

Risks

• The company faces challenges in maintaining revenue growth, particularly in product and collaboration revenue.
• The decrease in gross margin percentage could impact profitability.
• The company's cash reserves are decreasing, which may require future capital raises.
• The company is reliant on the success of its Gibson SOLA platform and BioXp mRNA solutions.
• The company is exposed to risks associated with the commercialization of new products and technologies.

Future Outlook

The Company will not be issuing additional forward-looking guidance at this time.

Management Comments

• President and CEO Eric Esser stated he is pleased with the company's performance as they execute their strategy to focus on Gibson SOLA and BioXp mRNA solutions.
• Eric Esser also mentioned that BioXp mRNA offerings are gaining traction and delivering improvements in speed and simplicity to customers.
• Eric Esser expressed excitement about the progress with Gibson SOLA and its potential to transform high-throughput on-demand synthesis of DNA and mRNA.

Industry Context

The announcement reflects a shift in focus towards mRNA solutions and the commercialization of the Gibson SOLA platform, aligning with the growing demand for advanced tools in drug discovery and synthetic biology. The company is positioning itself to compete in the rapidly evolving market for DNA and RNA synthesis technologies.

Comparison to Industry Standards

• Telesis Bio's revenue decline contrasts with the growth seen in some other biotech companies focused on synthetic biology and mRNA technologies, such as Moderna and BioNTech, although these companies are much larger and at a different stage of development.
• The 31% reduction in operating expenses is a positive sign, but the company needs to demonstrate revenue growth to achieve profitability.
• The gross margin of 42% is lower than some industry benchmarks for biotech companies, indicating potential pricing or cost challenges.
• The company's focus on Gibson SOLA and BioXp mRNA solutions aligns with industry trends towards automation and on-demand synthesis, but the company needs to demonstrate its competitive advantage against other players in the market.

Stakeholder Impact

• Shareholders may be concerned about the revenue decline and decreasing cash reserves.
• Employees may be impacted by the restructuring program and changes in commercial strategy.
• Customers may benefit from the company's focus on Gibson SOLA and BioXp mRNA solutions.
• Suppliers may be affected by changes in the company's purchasing patterns.
• Creditors may be concerned about the company's financial performance and decreasing cash reserves.

Next Steps

• The company will focus on expanding the adoption of Gibson SOLA for DNA and mRNA drug discovery applications.
• The company will continue to progress its strategic research collaboration with Pfizer.

Key Dates

Keywords

Telesis Bio, Gibson SOLA, BioXp, mRNA, DNA synthesis, financial results, biopharma, drug discovery, synthetic biology, Pfizer